Navigation Links
Drug Treatment Seekers Likely to Use Needle Exchange

A new study examined the connection between Baltimore City’s needle exchange program and drug treatment programs.//

Individuals who enter treatment programs for drug addiction were more likely to be HIV-positive females who use the Baltimore City needle exchange programs.

The study by researchers at the Johns Hopkins Bloomberg School of Public Health highlights the need for treatment facilities to address co-occurring problems, such as HIV and mental illness. It is published in the December 2006 edition of the journal Substance Use & Misuse.

“Needle exchange programs and drug user treatment centers are two effective strategies to reduce HIV infections and drug abuse,” explained Carl A. Latkin, PhD, lead author of the study and a professor in the Bloomberg School of Public Health’s Department of Health, Behavior and Society.

“Needle exchange programs reduce the number of contaminated syringes in a community and drug treatment reduces drug use, which may indirectly reduce HIV transmission.”

In their analysis, the study authors included 440 injection drug users who were interviewed from 1997 to 2002 as part of the Self-Help in Eliminating Life-Threatening Diseases (SHIELD) study. At follow-up, 166 of the study participants were enrolled in methadone maintenance or detoxification, or a drug-free residential or outpatient treatment program.

Individuals who entered treatment programs were more likely to be female, unemployed and participants in Baltimore City’s needle exchange program, compared with individuals who did not enter drug treatment programs. Those in treatment were also more likely to be HIV positive, have a history of mental illness and inject heroin. Individuals who did not enter treatment programs were more likely to sniff or snort cocaine or heroin.

“Needle exchange programs are an important part in linking drug users with treatment. Creating trusting relationships with health care p
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...ors of All India Institute of Medical Sciences (AI...ll //in Lok Sabha on Thursday intensified with fiv...ike - Dr Anil Sharma, spokesman of the AIIMS Resid...the doctors would continue attending duty and serv...
...Ease Dietary Supplement, a product containing the ...ndent on it when used just for few months. // Est...which should be consumed only under a practitioner...r of side effects like loss of memory, confusion, ...
... wish-list of many scientists and sufferers the wo...–child of an //Australian scientist, whose perseve...th of cancer cells, seems to have paid off. Prof...king on his ‘baby’ for the past 20 years, may just...
...mptoms of high fever and bodyache has killed 12 ch...g to official sources, 12 children died in two or ...strict due to the disease commonly referred as 'kh...a dozen children were suffering from the same dise...
Other Medicine News:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: